[HBME-1 immunostaining in thyroid pathology].
The aim of this study was to evaluate wether HBME-1 immunohistochemical analysis can reliably differentiate benign thyroid lesions from thyroid carcinomas. Fifty benign and 87 malignant lesions were analyzed. All papillary carcinomas (67/67) were HBME-1 positive, as well as 14 of 20 follicular well-differentiated carcinomas and 13 of 29 atypical follicular adenomas and 4 out of 21 goiters were weakly and focally positive. HBME-1 highlighted micronests of papillary carcinomas. The reactivity of HBME-1 in the tall-cell variant of papillary carcinomas was apical and stronger than in classical papillary carcinomas. Positive HBME-1 immunostaining is in support of the diagnosis of the follicular variant of papillary carcinoma and highlights micropapillary carcinomas. HBME-1 may be of additional value in the diagnosis of thyroid malignancy.
Laboratoire d'Anatomie Pathologique, Centre Hospitalo-Universitaire, Caen.
V
V
Rigau
B
B
Martel
C
C
Evrard
P
P
Rousselot
F
F
Galateau-Salle
D018263:Adenocarcinoma, Follicular / Q000737:chemistry / Q000473:pathology; D000911:Antibodies, Monoclonal; D000941:Antigens / Q000276:immunology; D002291:Carcinoma, Papillary / Q000737:chemistry; D004848:Epithelium / Q000276:immunology*; D006042:Goiter / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D013959:Thyroid Diseases / Q000378:metabolism* / Q000473:pathology; D013964:Thyroid Neoplasms / Q000737:chemistry / Q000473:pathology
D000911:Antibodies, Monoclonal; D000941:Antigens